Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 10:20PM GMT
Release Date Price: $15.75 (+0.96%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Hey, everyone. So thanks for joining us this afternoon. We're so excited to have the team from Syndax Pharmaceuticals here today to tell us kind of an update on where things are, where things are headed. So I'll let Mike Metzger give us some introductory remarks, then we'll just dive right in.

Michael A. Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Great. Well, thanks, Madhu. Thanks to the Goldman team for inviting us to the conference. It's a great venue. Great to see people in person. So I appreciate that. So most of you are familiar with Syndax, but just a reminder, we're a targeted oncology company, developing 2 agents in our pipeline, both are in registration trials for relapsed/refractory disease. Importantly, we have the opportunity to bring data -- pivotal data in 2023, the first half of 2023. So that's in the next 12 months as well as have regulatory filings, 2 regulatory filings in 2023. Both assets are poised to be first to market and best in class and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot